A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Ascendis Pharma Endocrinology Division A/S
- Target Recruit Count
- 900
- Registration Number
- NCT05820672
- Locations
- 🇺🇸
Ascendis Pharma Investigational Site, Centennial, Colorado, United States
A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Ascendis Pharma Endocrinology Division A/S
- Target Recruit Count
- 500
- Registration Number
- NCT05775523
- Locations
- 🇺🇸
Ascendis Pharma Investigational Site, Centennial, Colorado, United States
A Trial to Investigate Different Doses of Lonapegsomatropin Compared to Somatropin in Individuals With Turner Syndrome
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-01-19
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Ascendis Pharma Endocrinology Division A/S
- Target Recruit Count
- 48
- Registration Number
- NCT05690386
- Locations
- 🇺🇸
Ascendis Pharma Investigational Site, Seattle, Washington, United States
A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency
Phase 3
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-12-29
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Ascendis Pharma Endocrinology Division A/S
- Target Recruit Count
- 233
- Registration Number
- NCT05171855
- Locations
- 🇬🇧
Ascendis Pharma Investigational Site, Leeds, United Kingdom
A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Ascendis Pharma Endocrinology Division A/S
- Target Recruit Count
- 264
- Registration Number
- NCT04615273
- Locations
- 🇬🇧
Ascendis Pharma Investigational Site, Leeds, United Kingdom
A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-10-09
- Last Posted Date
- 2022-01-04
- Lead Sponsor
- Ascendis Pharma Endocrinology Division A/S
- Target Recruit Count
- 146
- Registration Number
- NCT03305016
- Locations
- 🇺🇸
Neufeld Medical Group Inc., Los Angeles, California, United States
🇺🇸Tallahassee Memorial Hospital, Tallahassee, Florida, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
- First Posted Date
- 2016-05-24
- Last Posted Date
- 2022-01-04
- Lead Sponsor
- Ascendis Pharma Endocrinology Division A/S
- Target Recruit Count
- 162
- Registration Number
- NCT02781727
- Locations
- 🇺🇦
Ascendis Pharma Investigational Site, Odesa, Ukraine
🇵🇱Ascendis Pharma Investigatonal Site, Gdańsk, Poland
© Copyright 2024. All Rights Reserved by MedPath